Antheia Secures $17 Million to Boost U.S. Production of Critical Pharmaceutical Ingredients
![](https://antheia.bio/wp-content/uploads/2024/07/Christina-Smolke-at-SynBioBeta2023-1.png)
Antheia, a pioneering pharmaceutical ingredient manufacturer, has announced a significant $17 million funding boost aimed at transforming the supply chains of essential medicines.
Antheia secures new funding to boost pharmaceutical ingredients production
![](https://antheia.bio/wp-content/uploads/2024/07/james-coleman-IMe6fLWEu6E-unsplash-1.png)
The company secured funding through government project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), alongside strategic investment from In-Q-Tel and Echo
Antheia Announces New Funding to Support Domestic Production of Critical Pharmaceutical Ingredients
![Press-Release-Thumbnail](https://antheia.bio/wp-content/uploads/2024/01/Press-Release-Thumbnail_Compressed-1024x768.webp)
Company awarded government project agreement to onshore key pharmaceutical supply chains, alongside strategic investment from In-Q-Tel and Echo
Addressing a Root Cause of Global Drug Shortages
![](https://antheia.bio/wp-content/uploads/2024/06/Pharmaceuticals_Pills_6-cropped.png)
The years-long journey medicines take from the farm to the pharmacy is a delicate one, vulnerable to extreme weather, mechanical failures, logistical and shipping delays, and geopolitical issues.
Antheia at SynBioBeta 2024: Scaling Highly Engineered Strains
![](https://antheia.bio/wp-content/uploads/2024/06/Kristy-blog-1024x768.jpeg)
Antheia was a proud sponsor of this year’s SynBioBeta, the Global Synthetic Biology Conference hosted annually in the San Francisco Bay Area.
Introducing Pavel Aronov, Senior Director, Bioanalytics
![](https://antheia.bio/wp-content/uploads/2024/06/Pavel.png)
Pavel and his team have developed the processes to accurately measure the quantity of our biosynthetic KSMs and APIs produced via biomanufacturing, which is no small feat when working with biological products
U.S. Secretary of State Antony J. Blinken Visits Antheia to Discuss Biotechnology Innovation
![](https://antheia.bio/wp-content/uploads/2024/05/SOS-blog-1.png)
In early May, U.S. Secretary of State Antony J. Blinken visited Antheia, HQ in Menlo Park, California for a tour of our labs and a panel discussion with innovators in the biotechnology industry
Secretary of State Antony J. Blinken Tours Antheia, Discusses the Importance of Biotechnology Innovation in the United States
![Press-Release-Thumbnail](https://antheia.bio/wp-content/uploads/2024/01/Press-Release-Thumbnail_Compressed-1024x768.webp)
Visit demonstrates U.S. commitment to bolstering the domestic biotechnology industry and onshoring critical supply chains, including pharmaceuticals Menlo Park, Calif., May 6, 2024 – Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today hosted Secretary of State Antony J. Blinken for a tour of its state of the art labs, as well as a discussion on biotechnology innovation and leadership in the United States. During his visit, Secretary Blinken met with a panel of industry and policy experts from Atomic AI, Ginkgo Bioworks, MycoWorks, Stanford University, and Twist Bioscience. The discussion was moderated by Christina Smolke, Ph.D., CEO and co-founder at Antheia and focused on the critical role of biotechnology to U.S. national and economic security, the need for strong international partnerships to develop solutions for global good, and the urgency to maintain U.S. leadership in this critical emerging technology. “We are grateful to Secretary Blinken for his time and attention today, as well as the U.S. government’s continued commitment to advancing biotechnology and biomanufacturing,” said Dr. Smolke, CEO and co-founder, Antheia. “With the ongoing support of both the public and private sectors, a future with resilient, sustainable pharmaceutical supply chains, minimal disruptions to critical drug supplies, and equitable access to essential medicines for all is well-within reach.” On September 12, 2022, President Biden issued Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy.” According to the White House, “global industry is on the cusp of an industrial revolution powered by biotechnology.” As part of the scope of the biomanufacturing executive order, the Department of State is working to promote and protect U.S. technologies and the global bioeconomy. By Antheia’s estimates, advanced biomanufacturing can enable domestic production of over 50 percent of the key starting materials (KSMs) and active pharmaceutical ingredients (APIs) underlying essential medicines at a fraction of the time and cost of conventional manufacturing. Antheia’s first product, thebaine, is a key ingredient used in the production of several drugs on the U.S. Food and Drug Administration and the World Health Organization’s Essential Medicines lists. Antheia’s processes have been validated at scale, demonstrating this technology’s viability, commercial-readiness, and societal impact. About AntheiaAntheia is the next-generation pharmaceutical ingredient producer transforming essential medicine supply chains to end drug shortages. Using its novel whole-cell engineering approach, Antheia’s biomanufacturing platform enables the reconstruction of biosynthetic pathways of unprecedented complexity in yeast cells and the scaling of fermentation processes to commercial levels. This highly flexible approach enables on-demand, agile, and resilient biomanufacturing of critical pharmaceutical ingredients, replacing legacy approaches that cannot support the needs of modern healthcare. For more information, visit www.antheia.bio. MEDIA CONTACT: Mission North for [email protected]
Secretary of State Antony Blinken visits the Bay Area
![SOS-visit](https://antheia.bio/wp-content/uploads/2024/05/SOS-visit-thumbnail.png)
Antony Blinken tours Antheia biotech lab, emphasizing its potential to address nationwide medicine shortages by overcoming supply chain issues with advanced bio-technology
Antheia CEO Keynotes at OECD Global Forum on Technology: Building our Bio Future
![](https://antheia.bio/wp-content/uploads/2024/04/OECD-STI-Global-Forum-on-Technology-High-level-Meeting-22nd-April-2024-1702-1024x718.jpg)
Last week, Antheia CEO and co-founder, Dr. Christina Smolke joined OECD’s Global Forum on Technology: Building our Bio Future as a keynote speaker. OECD (Organization for Economic Co-operation and Development) is an international organization bringing together government, academia, and industry to build global policies that foster prosperity and well-being for all. In her keynote address, Dr. Smolke discussed the transformative power of synthetic biology, its role in solving major challenges across industries including pharma supply chains, and how policy can support a flourishing synthetic biology industry. This forum brought together some of the brightest minds across the synthetic biology field from around the world. A recurring theme from the event’s discussions, both on- and off-stage, was the need to align stakeholders from all aspects of this international industry. The urgency to develop sustainable manufacturing solutions is rapidly increasing as natural resources are depleted and supply chains repeatedly falter. The global population is at risk of failing supply chains, but with a coordinated effort between industry, academia, government – specifically, policy, governance, and regulation – synthetic biology has the potential to fundamentally transform these legacy systems to better support the public at large. As a pioneer in the field of synthetic biology with more than 20 years of experience, Dr. Smolke offered a unique perspective on the evolution of this technology and its current role as an advanced manufacturing technology for critical pharmaceutical ingredients. Pharma is one of the most vital global supply chains, but it is also one of the most fragile and unreliable, with serious consequences (e.g. drug shortages, inadequate patient care) for human health when something goes awry. Synthetic biology offers an innovative solution to build resilient, agile, and sustainable supply chains for pharma, as well as other critical industries like food, agriculture, and industrial materials. As a global community, countries need to consider how to support and incentivize the advancement of synthetic biology to unlock benefits for all people and the planet. This could take the shape of public-private partnerships, funding, or policies that provide incentives to bring these innovative solutions to global markets. Synthetic biology is a powerful technology for solving major, global problems and is on the precipice of reaching its full potential. With the right policy, support, and prioritization from leaders like those present at OECD’s Global Forum on Technology event, we will continue to see growth and transformation stemming from synthetic biology innovation. Follow Antheia on LinkedIn and X/Twitter.